Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III immunogenicity and reactogenicity study of Fluarix Tetra in adults and older adults in Brazil
RBR-4bfx9cPhase 3Completed
- Sponsor
- GSK
- Start
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Fluarix Quadrivalent in influenza (2 cohorts), sponsored by GSK. Primary endpoints: Immunogenicity and Reactogenicity. Started Apr 2015; status: completed.
02
Drugs
Fluarix Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on RBR-4bfx9c.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4bfx9c.